Table 4.
Proportion of the different late reading skin-test-results and theirs 95% confidence intervals in patients with various delayed DHR-manifestation (%); [95%CI]
| Characteristics | Proportion combined late skin-test positive (intradermal or patch) | Proportion intradermal skin-test positive | Proportion patch test positive | Proportion positive results only patch test performed | |
|---|---|---|---|---|---|
| All Delayed DHR-manifestation n = 130 | 26/130 (20.0%), [14.0%–27.7%] | 15/111 (13.5%) [8.4%–21.1%] | 18/96 (18.8%) [12.2%–27.7%] | 9/19 (47.4% [27.3%–68.3%] | |
| Macular/maculopapular exanthema n = 92 | 18/86 (20.9%), [13.7–30.7%] | 12/76 (15.8%), [9.3%–25.6%] | 11/63 (17.5%) [10.0%–28.6%] | 4/10 (40.0%), [16.8–68.7%] | |
| Pustular exanthema, n = 4 | 2/4 (50%) [8.9–91.1%] | 2/4 (50%) [8.9–91.1%] | 2/4 (50%) [8.9–91.1%] | n/a | |
| bullous exanthema, n = 4 | 2/4 (50%) [8.9–91.1%] | 1/1 (100%), [5.1–100%] | 1/3 (33.3), [1.7–88.2%] | 1/3 (33.3), [1.7–88.2%] | |
| DRESS n = 4 | 3/4 (75.0%), [30.1%–98.7%] | n/a | 3/4 (75.0%), [30.1%–98.7%] | 3/4 (75.0%), [30.1%–98.7%] | |
| fixed drug eruption n = 3 | 0/3 (0%), [0.0–56.2%] | 0/2 (0%), [0.0–82.2%] | 0/3 (0%), [0.0–56.2%] | 0/1 (0%), [0.0–94.9%] | |
| Delayed urticaria/angioedema n = 13 | 0/13 (0%), [0.0–22.8%] | 0/13 (0%), [0.0–22.8%] | 0/6 (0%), [0.0–39.0%] | n/a | |
| Skin eruption including test site n = 84 | 26/84 (31.0%), [22.1–41.5%] | 15/71 (21.1%), [13.2–32.0%] | 18/55 (32.7%), [21.8–45.9%] | 9/13 (69.2%), [42.4–87.3%] | |
| Skin eruption excluding test site n = 38 | 0/38 (0%), [0.0–9.2%] | 0/34, (0%), [0.0–10.2%] | 0/35 (0%), [0.0–9.9%] | 0/4 (0%), [0.0–49.0%] | |
| interval from drug exposure to the onset | 0-3d | 18/61 (29.5%), [19.6–41.9%] | 12/54 (22.2%), [13.2–34.9%] | 11/43 (25.6%), [14.9–40.2%] | 4/7 (57.1%), [25.0–84.2%] |
| >3d | 8/69 (11.6%), [6.0–21.2%] | 3/57 (5.3%), [1.4–14.4%] | 7/51 (13.2%), [6.5–24.8%] | 5/12 (41.7%), [19.3–68.0%] | |
| interval between index reaction and allergy work-up | <2 m | 2/12 (16.7%), [3.0–44.8] | 1/8 (12.5%), [0.6–47.1%] | 1/10 (10.0%), [0.5–40.4%] | 1/4 (25.0%), [1.3–69.9] |
| 2–6 m | 14/61 (23.0%), [14.2–34.9%] | 5/48 (10.4%), [4.5–22.2%] | 13/48 (27.1%), [16.6–41.0%] | 8/13 (61.5%), [35.5–82.3%] | |
| 2 m -3 y | 20/87 (23.0%), [15.4–32.9%] | 11/73 (15.1%), [8.6–25.0%] | 15/64 (23.4%), [14.8–25.1%] | 8/14 (57.1%), [32.6–78.6%] | |
| >3years | 4/31 (12.9%), [5.1–28.9%] | 3/30 (10.0%), [3.5–25.6%] | 2/22 (9.1%), [1.6–27.8%] | 0/1 (SJS, LTT positive) | |